Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients

Daniel W. Hommer, Theodore P. Zahn, David Pickar, Daniel P. van Kammen

Research output: Contribution to journalArticle

Abstract

The specific α1-noradrenergic antagonist, prazosin, was administered to seven schizophrenic patients in a double-blind, placebo-controlled trial. Patients showed no change in any of their psychiatric symptoms as rated by nurses on global depression and psychosis scales and by physicians on the Brief Psychiatric Rating Scale. However, they did show a significant increase in autonomic arousal as measured by changes in skin conductance. The increased autonomic arousal is probably mediated by increases in plasma norepinephrine induced by chronic prazosin treatment.

Original languageEnglish (US)
Pages (from-to)193-204
Number of pages12
JournalPsychiatry Research
Volume11
Issue number3
DOIs
StatePublished - 1984
Externally publishedYes

Keywords

  • autonomic arousal
  • norepinephrine
  • prazosin
  • Schizophrenia
  • skin conductance
  • α-receptors

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Fingerprint Dive into the research topics of 'Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients'. Together they form a unique fingerprint.

  • Cite this